23andMe Launches Advanced Ancestry Features Including Reconstructed Ancestors and DNA Relatives Clustering

23andMe, a leading consumer genetics and research organization and nonprofit affiliate of the 23andMe Research Institute, today announced the launch of a...

March 16, 2026 | Monday | News
Novartis’ Cosentyx Approved by FDA for Adolescents with Moderate to Severe Hidradenitis Suppurativa

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3  HS often e...

March 16, 2026 | Monday | News
iXCells Delivers 500+ Patient-Derived iPSC Lines, Demonstrating Industrial-Scale Drug Discovery Platform

iXCells Biotechnologies USA, Inc. (“iXCells”), a leading provider of human cell-based solutions and custom iPSC services,  announced the d...

March 16, 2026 | Monday | News
Clearmind Advances CMND-100 Clinical Program with Third Cohort Enrollment in Phase I/IIa AUD Trial

Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and developm...

March 13, 2026 | Friday | News
Medisolv Acquires Lilac Software to Expand AI-Driven Quality Intelligence for Value-Based Care

Collaboration brings together clinical and claims-based quality intelligence with agentic AI to help healthcare organizations close care gaps and succeed...

March 11, 2026 | Wednesday | News
Incyte Secures EU Approval for Zynyz Combination Therapy in Advanced Anal Cancer

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult pati...

March 10, 2026 | Tuesday | News
Daiichi Sankyo and AstraZeneca Secure FDA Priority Review for Enhertu in HER2-Positive Early Breast Cancer

Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/NYSE: AZN) supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzuma...

March 10, 2026 | Tuesday | News
GenSight Biologics Advances Early Access Programs for LUMEVOQ Gene Therapy in Rare Vision Disorder

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene...

March 10, 2026 | Tuesday | News
Agilent Technologies to Acquire Biocare Medical for $950 Million to Strengthen Global Pathology Portfolio

Expands Agilent’s pathology portfolio through addition of highly complementary antibody, reagent and instrument business with annual double-digit...

March 10, 2026 | Tuesday | News
Bayer Secures FDA Clearance Expanding Capabilities of MEDRAD MRXperion MR Injection System

Clearance reinforces Bayer’s continued commitment to dependable, integrated radiology solutions Expanded Tesla compatibility captures low- to ...

March 06, 2026 | Friday | News
ImmunoScape Advances Seed And Boost Cancer Therapy Programme With United States Clinical Collaboration

The company also announced a strategic investment from Leonardo DiCaprio ImmunoScape Pte. Ltd., an A*STAR spin-out backed by Amgen Ventures an...

March 06, 2026 | Friday | News
Allosteric Bioscience Advances Integrated Platform To Decode And Control Molecular Drivers Of Aging

Allosteric Bioscience, Inc. is utilizing Genetics, Genomics, Systems Biology, Quantum Computing, Advanced Proprietary AI and Proprietary Molecular ...

March 06, 2026 | Friday | News
Codexis, Inc. Advances RNA Manufacturing with 50g siRNA Production Agreement for Cardiovascular Program

Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing,  announced it has ent...

March 06, 2026 | Friday | News
Former BioDuro Leadership Launches Forma Life Sciences as Independent CDMO

-Forma Life Sciences, Inc. announced its launch as an independent, operator-owned contract development and manufacturing organization (CDMO) focused on o...

March 05, 2026 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close